©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 112530
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.112530
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.112530
Table 6 Alpha fetoprotein and telomere length before and after treatment between the hepatocellular carcinoma and chronic liver disease groups
| Variables | HCC group (total = 30) | CLD group (total = 30) | P value | |||
| Before | After | Before | After | |||
| AFP (ng/mL) | Median (1st-3rd IQ) | 31.5 (6.2-235.0) | 11.5 (4.2-101.0) | 11.5 (4.2-101.0) | 0.198 | 0.999 |
| Range | 0.9-800.0 | 0.8-388.0 | 0.8-388.0 | |||
| Telomere length (× 103) | Median (1st-3rd IQ) | 1.3 (1.0-1.8) | 1.6 (1.0-1.9) | 1.4 (1.1-1.9) | 0.626 | 0.647 |
| Range | 0.5-3.5 | 0.6-5.3 | 0.4-7.6 | |||
- Citation: El-Nakeep S, AbdelAziz H, Michael TG, ElGhandour AM, Abdelsattar HA, Awad FMR, Kasi A. Clinical utility of telomeres as diagnostic and short-term prognostic markers in loco-regional treatment of hepatocellular carcinoma. World J Gastroenterol 2025; 31(46): 112530
- URL: https://www.wjgnet.com/1007-9327/full/v31/i46/112530.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i46.112530